Mirum Pharmaceuticals completes enrollment in liver disease drug study

March 16, 2026 8:00 AM

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) announced completion of enrollment in its Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for treating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found